

September 21, 2020



## Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC

SOUTH SAN FRANCISCO, Sept. 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company today announced that it has been recognized as Best New Drug Developer at the World ADC Digital Awards, held during the World ADC Digital Event.

"We are honored to receive the World ADC Best New Drug Developer Award," said Bill Newell, Sutro's Chief Executive Officer. "The award recognizes our three innovative clinical development candidate ADCs. STRO-001 and STRO-002 are currently in Phase 1 clinical studies and CC-99712 is under investigation in a Phase 1b/2 clinical trial by our partner Bristol Myers Squibb. We are encouraged by our emerging and promising clinical data and the patient benefit that these product candidates may offer."

Our unique, rapid and precise protein engineering technology is focused on the design and manufacture of homogeneous potential best-in-class oncology therapeutics. In addition to the three clinical candidates, two more are projected to enter the clinic in 2021. "The presentation of this award to Sutro is particularly pleasing given that it represents recognition by some of the most talented professionals in the biopharmaceutical industry. It is a tribute to the innovation, commitment and contributions of our talented Sutro team," said Dr. Trevor Hallam, Sutro's Chief Scientific Officer.

The World ADC Awards showcases companies, teams and individuals in the industry, across 9 categories, at the forefront of cancer research today. Finalists and winners were shortlisted from over 1,000 votes cast and each submission was evaluated by a panel of seven judges.

### **About Sutro Biopharma**

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Sutro's proprietary and integrated cell-free protein synthesis platform XpressCF<sup>®</sup> and site-specific conjugation platform XpressCF+<sup>™</sup> led to the discovery of STRO-001 and STRO-002, Sutro's first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma. STRO-001 was granted Orphan Drug Designation by the FDA for multiple myeloma in October 2018. STRO-002 is a folate receptor alpha (FolR $\alpha$ )-targeting ADC, currently being investigated in a Phase 1 clinical trial of patients with ovarian and endometrial cancers. This is the second product candidate to be evaluated in clinical trials resulting from Sutro's XpressCF<sup>®</sup> and XpressCF+<sup>™</sup> technology platforms. A third program, CC-99712 (BCMA-targeting ADC), which is part of Sutro's collaboration with Bristol Myers Squibb (formerly Celgene

Corporation), is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma. Sutro's proprietary technology was responsible for the discovery and manufacturing of CC-99712, for which Bristol Myers Squibb has worldwide development and commercialization rights. Sutro is entitled to development and regulatory milestone payments and tiered royalties from Bristol Myers Squibb for this BCMA ADC. Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.

To date, Sutro has designed cytokine-based immuno-oncology therapies, ADCs, vaccines and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.

Sutro's platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.

In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.

Additional multimedia content from Sutro regarding STRO-001 and STRO-002 can be found [here](#) and [here](#).

Follow Sutro on Twitter, [@SutroBio](#), and at [www.sutroBio.com](http://www.sutroBio.com) to learn more about our passion for changing the future of oncology.

### **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, timing of clinical trials and announcements of clinical results, potential benefits of the company's product candidates and platform and potential market opportunities for the company's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the impact of the COVID-19 pandemic on the Company's business, clinical trial sites, supply chain and manufacturing facilities, the Company's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical studies and clinical trials, the company's ability to fund development activities and achieve development goals, the company's ability to protect intellectual property, and the Company's commercial collaborations with third parties and other risks and

uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

### **Investor Contacts**

John Graziano  
Solebury Trout  
+1 646-378-2942  
[jgraziano@soleburytrout.com](mailto:jgraziano@soleburytrout.com)

Xuan Yang  
Solebury Trout  
+1 646-378-2975  
[xyang@soleburytrout.com](mailto:xyang@soleburytrout.com)

### **Media Contacts**

David Schull  
Russo Partners  
(212) 845-4271  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

Maggie Beller  
Russo Partners  
(646) 942-5631  
[maggie.beller@russopartnersllc.com](mailto:maggie.beller@russopartnersllc.com)

🔗 View original content:<http://www.prnewswire.com/news-releases/sutro-biopharma-named-best-new-drug-developer-at-the-7th-annual-world-adc-301134256.html>

SOURCE Sutro Biopharma